- TLDR Biotech
- Archive
- Page 8
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | July 2 - 4, 2024
Beacon Therapeutics raises $170M Series B, Pentixapharm acquires Glycotope's antibody discovery arm, J&J lands FDA and EMA approval for multi-drug resistant TB therapy, and CureVac sells its Covid-19/flu assets while also laying off 30% of their staff
Biotech & Pharma Updates | June 28 - July 1, 2024
Eli Lilly makes another radiopharma deal, Samsung's Stelara biosimilar gets FDA approval, Boehringer Ingelheim begins Ph1 for "first-in-class" obesity treatment, Takeda sheds over 200 MA-based staffers, and lone Ph1 ultra-rare disease gene therapy patient makes stellar improvements
Biotech & Pharma Updates | June 27 - 30, 2024
Abbvie, Regeneron, Merck & Co. all land CHMP panel recommendations (while Apellis and PTC both get thumbs down), Lantheus buys radiophama assets, Ensho Therapeutics launches with Eisai assets, and former Cassava Sciences scientific advisor gets indicted
Biotech & Pharma Updates | June 26 - 27, 2024
Novo Nordisk buys 2seventy bio's hemophilia A asset, worm-derived therapies raise $16M, Abbvie buys Celsius Therapeutics for $250M, Kite Pharma to evaluate Cellares' cell therapy manufacturing platform, and Merck, Daiichi Sankyo's lung cancer mAb hit with FDA CRL
Biotech & Pharma Updates | June 24 - 25, 2024
Otsuka and Lundbeck’s PTSD sNDA filing accepted, Exsilio launches with $82M and big name investors, Zealand Pharma ups equity offering to $1B, Eli Lilly & OpenAI sign an antibiotic drug discovery pact, and Abbvie's Parkinson's med gets hit with a CRL
Biotech & Pharma Updates | June 22 - 24, 2024
Alnylam’s slam dunk Ph3 heart disease data, Pfizer tapped to supply RSV vaccine to the UK, Novo Nordisk shares detailed hemophilia A Ph3 data, Novo Nordisk earmarks $4.1B for NC manufacturing plant, and Merck KGaA cuts a Ph3 cancer trial short
